Phase III EF-14 Trial Shows Tumor Treating Fields Improve OS in Brain Cancer

November 19, 2016
Roger Stupp, MD

Results from the EF-14 trial which compared standard of care for glioblastoma plus or minus the tumor treating fields. 

Roger Stupp, MD, professor of oncology, University of Zurich, discusses the EF-14 trial which compared standard of care for glioblastoma plus or minus tumor treating fields with Optune. Median overall survival was 20.8 months for temozolomide plus Optune versus 16.0 months for temozolomide-alone (HR, 0.65; 95% CI, 0.54-0.79;P